COVAXIN
Senate probe seeks to charge Jair Bolsonaro as COVID deaths cross 600k and other stories

Today we look at an upcoming senate report on the Brazilian government’s COVID-19 response, the trial of Egyptian officers in the murder of Italian researcher Giulio Regeni, and more

Why is India’s Covaxin not being recognized internationally?

As debates heat up on various rules and regulations on commuting during the pandemic, Dr. Satyajit Rath talks about the xenophobic nature of the current international restrictions on air travel

Yet another study shows how mass vaccinations win over COVID

In this show, immunologist Prof. Satyajit Rath sheds light on issues of vaccine equity, possibility of mass inoculation, the need for booster shots and more

COVID-19 in India: A tale of crumbling health systems and political one-upmanship

India’s government had a year to ramp up its health infrastructure. Instead, crucial time was lost in denial, underestimation, political one-upmanship and blame games

Indian govt. should properly explain vaccine doses gap: Satyajit Rath

Immunologist Dr. Satyajit Rath and Newsclick’s Prabir Purkayastha talk about the Indian government’s decision to extend the interval between doses

Bill Gates, the white man’s burden and Modi government’s vaccine debacle

An incompetent, vainglorious leadership, combined with the right-wing belief in magical capitalism, has led to the disaster that India is now facing

Why do we need global vaccination?

Newsclick’s Prabir Purkayastha and immunologist Dr. Satyajit Rath discuss the politics, economics and technical aspects of the global vaccine scenario in light of Bill Gates’ recent statement on technology transfer

What can India learn from its response to the pandemic?

It has been one year since the Narendra Modi government in India imposed a nationwide lockdown in response to the COVID-19 pandemic.

MSF reports civilians killed by Ethiopian soldiers in Tigray and other stories

Today we take a look at recent reports of the killing of civilians in the Tigray region, custodial deaths of Indigenous people in Australia, police repression against a protest in Jordan, and the key lessons learned as India marks 1 year of the Covid-19 lockdown

Covaxin trials: What 81% “interim efficacy” means

Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the “first interim analysis” of phase-3 trials.

In India, pseudo-nationalism trumps science in vaccine clearance

The recent regulatory clearance given to an indigenous developed vaccine candidate in India is an example of vaccine nationalism at its worst and jettisoning of all the principles of an evidence-based, scientific approach

COVID-19 Vaccines: Moderna declares successful trial results after Pfizer

The new vaccine candidate by Moderna Inc, called mRNA-1273, has reportedly shown 94.5% efficacy against the SARS-CoV-2 in the phase III clinical trials

    × To Subscribe